Consistent with a previous report, TMB and PD-L1 expression were found to be significantly lower in NTRK fusion-positive head and neck cancer specimens compared to fusion-negative cases (Figures 6A,B), suggesting these NTRK fusions are the dominant targetable oncogenic drivers (Xu et al., 2021). This evidence concerns the gene CD274 and head and neck cancer.